Sulbactam-containing beta-lactamase inhibitor combinations


Akova M.

CLINICAL MICROBIOLOGY AND INFECTION, vol.14, pp.185-188, 2008 (Journal Indexed in SCI) identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 14
  • Publication Date: 2008
  • Doi Number: 10.1111/j.1469-0691.2007.01847.x
  • Title of Journal : CLINICAL MICROBIOLOGY AND INFECTION
  • Page Numbers: pp.185-188

Abstract

Sulbactam irreversibly inhibits the hydrolytic activity of beta-lactamases. This compound is commercially available in combination with either ampicillin or cefoperazone. In each instance, the activity of the partner antibiotic against P-lactamase-producing bacteria is restored. One of the particular advantages of using sulbactam-containing combinations is that sulbactam itself has inherent activity against some Acinetobacter baumannii. Sulbactam combinations have not demonstrated strong selective pressures for extended-spectrum beta-lactamase-producing Enterobacteriaceae and vancomycin-resistant enterococci. In contrast to clavulanate, sulbactam does not induce class I (Ampc) chromosomal beta-lactamases in Enterobacteriaceae.